Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has been awarded a contract with UroGPO, the largest group purchasing organization for urology private practice clinics in the US, to make its bone pain treatment Strontium89 available to doctors.
Corin says through the partnership, UroGPO will support the establishment of Strontium89 injections as an added radionuclide therapeutic choice for patients with painful bone metastases from prostate and other urological cancers.